Paul R Brakeman, MD
Nephrology · San Francisco
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 12
- 2 carriers
- Offices
- 3
- Since medical school
- 29 years
- Graduated 1997
Offices
3 locations · University of California San Francisco · UCSF Pediatrics Associates
Looking this up.
Plans that list them
12 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Brakeman’s office at (415) 476-1000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
12 of 12 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
California Medical Board record
Licence A68014 · Current
Licensed to practise in California · since 1999 · expires 2027-01-31 · Johns Hopkins University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Pediatrics - Pediatric Nephrology
Medicaid work
$34,687 in 2024
Medicaid paid $34,687 for 258 billed services this clinician did in 2024, up to 21 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Long return visit (40+ min) | 149 | $24,807 |
| Return visit (30+ min) | 73 | $9,548 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 12 | $127 |
| Measurement of magnesium | 12 | $109 |
| Telehealth transmission, per minute, professional services bill separately | 12 | $96 |
| 2024 | 258 | 5 | 21 | $34,687 |
| 2023 | 440 | 3 | 30 | $47,441 |
| 2022 | 2,647 | 17 | 165 | $169,037 |
| 2021 | 8,601 | 8 | 553 | $482,947 |
| 2020 | 512 | 3 | 29 | $50,797 |
| 2019 | 482 | 1 | 43 | $62,711 |
| 2018 | 550 | 1 | 42 | $59,879 |
See the largest Medicaid services in earlier years
2023
| Long return visit (40+ min) | 245 | $34,745 |
| Return visit (30+ min) | 126 | $11,983 |
| Telehealth transmission, per minute, professional services bill separately | 69 | $713 |
2022
| Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose | 596 | $32,301 |
| Long return visit (40+ min) | 193 | $29,551 |
| Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; booster dose | 444 | $24,105 |
| Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose | 356 | $19,083 |
| Return visit (30+ min) | 182 | $18,047 |
| Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; second dose | 187 | $10,126 |
| Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; first dose | 136 | $7,249 |
| Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, booster dose | 88 | $5,896 |
| Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; booster dose | 107 | $5,738 |
| Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; booster dose | 61 | $4,087 |
| Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, booster dose | 58 | $3,886 |
| Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; first dose | 46 | $2,461 |
2021
| Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; first dose | 3,705 | $195,535 |
| Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; second dose | 3,507 | $186,315 |
| Long return visit (40+ min) | 243 | $33,991 |
| Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose | 577 | $30,856 |
| Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose | 332 | $17,789 |
| Return visit (30+ min) | 128 | $12,290 |
| Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; booster dose | 94 | $5,056 |
| Short return visit (20+ min) | 15 | $1,115 |
2020
| Long return visit (40+ min) | 285 | $37,302 |
| Return visit (30+ min) | 133 | $12,838 |
| Telehealth transmission, per minute, professional services bill separately | 94 | $656 |
2019
| Long return visit (40+ min) | 482 | $62,711 |
2018
| Long return visit (40+ min) | 550 | $59,879 |
Drugs they prescribed that Part D paid
$1,871
Pharmacies billed $1,871 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 14) in 2024. Too few prescriptions to judge: with under about 50 a year, a handful of patients can swing this share.
14 generic and 0 brand-name prescriptions · $1,871 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
Year by year
| 2024 | 14 | None | 0% (0) | 0% | $1,871 |
| 2022 | 14 | None | 0% (0) | None | $8,670 |
| 2021 | 70 | None | 0% (0) | 16% | $14,146 |
| 2020 | 91 | None | 0% (0) | None | $28,006 |
| 2019 | 48 | None | 0% (0) | None | $19,926 |
| 2018 | 40 | None | None | None | $22,854 |
| 2017 | 42 | None | 0% (0) | None | $11,664 |
| 2016 | 66 | None | None | None | $16,540 |
| 2015 | 50 | None | 0% (0) | None | $21,434 |
| 2014 | 33 | None | 0% (0) | None | $21,701 |
| 2013 | 114 | 13 | None | 22% | $48,488 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2021: 1 drug
| Prednisone | 12 | $82 | $7 |
2020: 2 drugs
| Calcitriol | 15 | $1,681 | $112 |
| Metoprolol | 11 | $80 | $7 |
2016: 1 drug
| Clonidine | 11 | $1,619 | $147 |
2015: 1 drug
| Amlodipine Besylate | 29 | $72 | $2 |
2014: 1 drug
| Amlodipine Besylate | 11 | $53 | $5 |
Money from drug and device companies
$1,975 in 2021
| 2021 | 1 | 1 | $1,975 | $1,975 |
| 2020 | 2 | 2 | $2,160 | $2,178 |
| 2019 | 1 | 1 | $400 | $400 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Alnylam Pharmaceuticals | Oxlumo | $1,975 | 1 payment
|
See the published payment
| Alnylam Pharmaceuticals | Consulting · 2021-12-14 | Oxlumo | $1,975 |
See earlier years (2020, 2019)
2020: $2,178
| Horizon Therapeutics plc | Procysbi | $2,160 | 1 payment
|
| Alexion Pharmaceuticals | Ultomiris | $18 | 1 payment
|
2019: $400
| Jazz Pharmaceuticals | None | $400 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 74.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1447295167
- Licence
- CA A68014California A68014: Current · expires 2027-01-31
- Group
- University of California San Francisco · UCSF Pediatrics Associates
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- CA 00A680140
- Taxonomy
- Pediatrics (208000000X)
- Mailing address
- 1635 Divisadero Street, Suite 625, Box 1821, San Francisco, CA, 94143
- NPI first listed
- 2006-06-17
- NPI last updated
- 2026-07-13
This is when the NPI record was last certified, not a medical board exam.